Paper

Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial

European Urology Oncology · 2026 · Niven Mehra, Noel W Clarke, Andrew J Armstrong et al.